Bridging pharmacology and neurodevelopment in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 10, Issue 6, 2007, Pages 713-716

  Kato, Tadafumi ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXTRO SERINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; DELUSION; DISEASE COURSE; DRUG MECHANISM; GENE EXPRESSION; GENETIC ANALYSIS; HALLUCINATION; HEREDITY; HIPPOCAMPUS; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SERINE;

EID: 35648954545     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007936     Document Type: Review

References (29)

1. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, Hamaguchi H, Toru M (1994). Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343, 703-704.
2. Detera-Wadleigh SD, McMahon FJ (2006). G72/G30 in schizophrenia and bipolar disorder : review and meta-analysis. Biological Psychiatry 60, 106-114.
3. Fujii K, Maeda K, Hikida T, Mustafa AK, Balkissoon R, Xia J, Yamada T, Ozeki Y, Kawahara R, Okawa M, et al. (2006). Serine racemase binds to PICK1: potential relevance to schizophrenia. Molecular Psychiatry 11, 150-157.
4. Fujiwara Y, Kazahaya Y, Nakashima M, Sato M, Otsuki S (1987). Behavioral sensitization to methamphetamine in the rat : an ontogenic study. Psychopharmacology (Berlin) 91, 316-319.
5. Hashimoto A, Nishikawa T, Hayashi T, Fujii N, Harada K, Oka T, Takahashi K (1992). The presence of free D-serine in rat brain. FEBS Letters 296, 33-36.
6. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, et al. (2003). Decreased serum levels of D-serine in patients with schizophrenia : evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 60, 572-576.
7. Ishimaru M, Kurumaji A, Toru M (1992). NMDA-associated glycine binding site increases in schizophrenic brains. Biological Psychiatry 32, 379-381.
8. Ito T, Hiraoka S, Kuroda Y, Ishii S, Umino A, Kashiwa A, Yamamoto N, Kurumaji A, Nishikawa T (2007). Effects of schizophrenomimetics on the expression of the CCN1 (CYR 61) gene encoding a matricellular protein in the infant and adult neocortex of the mouse and rat. International Journal of Neuropsychopharmacology. Published online : 4 July 2007. doi:10.1017/S1461145707007882.
9. Kajii Y, Muraoka S, Hiraoka S, Fujiyama K, Umino A, Nishikawa T (2003). A developmentally regulated and psychostimulant-inducible novel rat gene mrt1 encoding PDZ-PX proteins isolated in the neocortex. Molecular Psychiatry 8, 434-444.
10. Kumashiro S, Hashimoto A, Nishikawa T (1995). Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Research 681, 117-125.
11. Lieberman JA, Kane JM, Alvir J (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berlin) 91, 415-433.
12. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams Jr. DL, Sur C, Kinney GG (2006). Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Current Topics in Medicinal Chemistry, 6, 771-785.
13. Martineau M, Baux G, Mothet JP (2006). D-serine signalling in the brain : friend and foe. Trends in Neuroscience 29, 481-491.
14. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, Clair DM, Muir WJ, Blackwood DH, Porteous DJ (2000). Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics 9, 1415-1423.
15. Nishikawa T (2005). Metabolism and functional roles of endogenous D-serine in mammalian brains. Biological & Pharmaceutical Bulletin 28, 1561-1565.
16. Nishikawa T, Umino A, Kashiwa A, Ooshima A, Nomura N, Takahashi K (1993). Stimulant-induced behavioral sensitization and cerebral neurotransmission. In : Toru M (Ed.), Neurotransmitters in Neuronal Plasticity and Psychiatric Disorders (pp. 53-62). Tokyo: Excerpta Medica.
17. Nishikawa T, Umino A, Tanii Y, Hashimoto A, Hata N, Takashima M, Takahashi K, Toru M (1991). Dysfunction of excitatory amino acidergic systems and schizophrenic disorders. In : Nakazawa T (Ed.), Biological Basis of Schizophrenic Disorders (pp. 5-76). Tokyo and Basel : Japan Scientific Societies Press and Karger.
18. Ozeki Y, Tomoda T, Kleiderlein J, Kamiya A, Bord L, Fujii K, Okawa M, Yamada N, Hatten ME, Snyder SH, et al. (2003). Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proceedings of the National Academy of Sciences USA100, 289-294.
19. Rapoport JL, Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ (1978). Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199, 560-563.
20. Sato D, Umino A, Kaneda K, Takigawa M, Nishikawa T (1997). Developmental changes in distribution patterns of phencyclidine-induced c-Fos in rat forebrain. Neuroscience Letters 239, 21-24.
21. Sato M, Numachi Y, Hamamura T (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bulletin 18, 115-122.
22. Scalzo FM, Holson RR (1992). The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicology and Teratology 14, 7-14.
23. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 71, 877-892.
24. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, et al. (2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics, 71, 337-348.
25. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR (1990). Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. New England Journal of Medicine 322, 789-794.
26. Taniguchi G, Yamamoto N, Tsuchida H, Umino A, Shimazu D, Sakurai S, Takebayashi H, Nishikawa T (2005). Cloning of a D-serine-regulated transcript dsr-2 from rat cerebral neocortex. Journal of Neurochemistry 95, 1541-1549.
27. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1991). Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Research 563, 281-284.
28. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1994). Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. Journal of Pharmacology and Experimental Therapeutics 269, 1040-1048.
29. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, et al. (2005). Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biological Psychiatry 57, 1493-1503.